Dynavax Technologies (NASDAQ:DVAX) Announces Earnings Results

Dynavax Technologies (NASDAQ:DVAX) issued its earnings results on Wednesday. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.07, Zacks reports. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%. The business had revenue of $94.88 million for the quarter, compared to analysts’ expectations of $94.00 million.

Dynavax Technologies Stock Up 7.1%

Shares of NASDAQ DVAX traded up $0.74 on Thursday, reaching $11.04. 1,721,033 shares of the company’s stock traded hands, compared to its average volume of 1,976,243. Dynavax Technologies has a 12 month low of $9.20 and a 12 month high of $14.63. The business’s 50 day simple moving average is $9.99 and its two-hundred day simple moving average is $10.28. The company has a market cap of $1.29 billion, a price-to-earnings ratio of -23.92 and a beta of 1.09. The company has a quick ratio of 6.01, a current ratio of 6.65 and a debt-to-equity ratio of 0.45.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on DVAX. JMP Securities reissued a “market outperform” rating and set a $32.00 target price on shares of Dynavax Technologies in a report on Friday, August 22nd. Wall Street Zen raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Dynavax Technologies in a report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Dynavax Technologies has an average rating of “Hold” and an average price target of $24.33.

Insider Buying and Selling at Dynavax Technologies

In other news, Director Scott Dunseth Myers purchased 3,800 shares of the business’s stock in a transaction dated Friday, August 22nd. The shares were purchased at an average price of $10.82 per share, for a total transaction of $41,116.00. Following the completion of the acquisition, the director directly owned 35,004 shares in the company, valued at $378,743.28. This represents a 12.18% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 2.98% of the company’s stock.

Institutional Investors Weigh In On Dynavax Technologies

A number of institutional investors have recently made changes to their positions in the company. Envestnet Asset Management Inc. grew its holdings in shares of Dynavax Technologies by 55.3% during the third quarter. Envestnet Asset Management Inc. now owns 20,888 shares of the biopharmaceutical company’s stock valued at $207,000 after buying an additional 7,441 shares during the last quarter. Osaic Holdings Inc. grew its holdings in shares of Dynavax Technologies by 15.1% during the second quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock valued at $93,000 after buying an additional 1,226 shares during the last quarter. State of Wyoming purchased a new stake in shares of Dynavax Technologies during the second quarter valued at approximately $304,000. Tower Research Capital LLC TRC grew its holdings in shares of Dynavax Technologies by 319.8% during the second quarter. Tower Research Capital LLC TRC now owns 16,239 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 12,371 shares during the last quarter. Finally, E Fund Management Co. Ltd. grew its holdings in shares of Dynavax Technologies by 17.9% during the second quarter. E Fund Management Co. Ltd. now owns 18,113 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 2,752 shares during the last quarter. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.